Kandalaft LE - Search Results

1

Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING.

Bruand M, Barras D, Mina M, Ghisoni E, Morotti M, Lanitis E, Fahr N, Desbuisson M, Grimm A, Zhang H, Chong C, Dagher J, Chee S, Tsianou T, Dorier J, Stevenson BJ, Iseli C, Ronet C, Bobisse S, Genolet R, Walton J, Bassani-Sternberg M, Kandalaft LE, Ren B, McNeish I, Swisher E, Harari A, Delorenzi M, Ciriello G, Irving M, Rusakiewicz S, Foukas PG, Martinon F, Dangaj Laniti D, Coukos G. Bruand M, et al. Among authors: kandalaft le. Cell Rep. 2021 Jul 20;36(3):109412. doi: 10.1016/j.celrep.2021.109412. Cell Rep. 2021. PMID: 34289354 Free PMC article.

2

Endothelin B receptor, a new target in cancer immune therapy.

Kandalaft LE, Facciabene A, Buckanovich RJ, Coukos G. Kandalaft LE, et al. Clin Cancer Res. 2009 Jul 15;15(14):4521-8. doi: 10.1158/1078-0432.CCR-08-0543. Epub 2009 Jun 30. Clin Cancer Res. 2009. PMID: 19567593 Free PMC article. Review.

3

The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade.

Kandalaft LE, Singh N, Liao JB, Facciabene A, Berek JS, Powell DJ Jr, Coukos G. Kandalaft LE, et al. Gynecol Oncol. 2010 Feb;116(2):222-33. doi: 10.1016/j.ygyno.2009.11.001. Epub 2009 Dec 2. Gynecol Oncol. 2010. PMID: 19959212 Free PMC article. Review.

4

Angiogenesis and the tumor vasculature as antitumor immune modulators: the role of vascular endothelial growth factor and endothelin.

Kandalaft LE, Motz GT, Busch J, Coukos G. Kandalaft LE, et al. Curr Top Microbiol Immunol. 2011;344:129-48. doi: 10.1007/82_2010_95. Curr Top Microbiol Immunol. 2011. PMID: 20680802 Review.

5

Immunotherapy for ovarian cancer: what's next?

Kandalaft LE, Powell DJ Jr, Singh N, Coukos G. Kandalaft LE, et al. J Clin Oncol. 2011 Mar 1;29(7):925-33. doi: 10.1200/JCO.2009.27.2369. Epub 2010 Nov 15. J Clin Oncol. 2011. PMID: 21079136 Free PMC article. Review.

6

Tumor immune surveillance and ovarian cancer: lessons on immune mediated tumor rejection or tolerance.

Kandalaft LE, Motz GT, Duraiswamy J, Coukos G. Kandalaft LE, et al. Cancer Metastasis Rev. 2011 Mar;30(1):141-51. doi: 10.1007/s10555-011-9289-9. Cancer Metastasis Rev. 2011. PMID: 21298574 Review.

7

Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines.

Chiang CL, Kandalaft LE, Coukos G. Chiang CL, et al. Among authors: kandalaft le. Int Rev Immunol. 2011 Apr-Jun;30(2-3):150-82. doi: 10.3109/08830185.2011.572210. Int Rev Immunol. 2011. PMID: 21557641 Review.

8

Optimizing parameters for clinical-scale production of high IL-12 secreting dendritic cells pulsed with oxidized whole tumor cell lysate.

Chiang CL, Maier DA, Kandalaft LE, Brennan AL, Lanitis E, Ye Q, Levine BL, Czerniecki BJ, Powell DJ Jr, Coukos G. Chiang CL, et al. Among authors: kandalaft le. J Transl Med. 2011 Nov 14;9:198. doi: 10.1186/1479-5876-9-198. J Transl Med. 2011. PMID: 22082029 Free PMC article.

9

Day-4 myeloid dendritic cells pulsed with whole tumor lysate are highly immunogenic and elicit potent anti-tumor responses.

Chiang CL, Hagemann AR, Leskowitz R, Mick R, Garrabrant T, Czerniecki BJ, Kandalaft LE, Powell DJ Jr, Coukos G. Chiang CL, et al. Among authors: kandalaft le. PLoS One. 2011;6(12):e28732. doi: 10.1371/journal.pone.0028732. Epub 2011 Dec 14. PLoS One. 2011. PMID: 22194898 Free PMC article.

10

A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer.

Kandalaft LE, Powell DJ Jr, Coukos G. Kandalaft LE, et al. J Transl Med. 2012 Aug 3;10:157. doi: 10.1186/1479-5876-10-157. J Transl Med. 2012. PMID: 22863016 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

89 results

Search Page